

# Jürgen Burhenne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3444080/publications.pdf>

Version: 2024-02-01

201  
papers

7,172  
citations

44069

48  
h-index

76900

74  
g-index

201  
all docs

201  
docs citations

201  
times ranked

7338  
citing authors

#	ARTICLE	IF	CITATIONS
1	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. <i>Cell</i> , 2020, 182, 1252-1270.e34.	28.9	259
2	Binding of Fluoroquinolone Carboxylic Acid Derivatives to Clay Minerals. <i>Journal of Agricultural and Food Chemistry</i> , 1997, 45, 1459-1463.	5.2	248
3	CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 196-204.	2.0	174
4	Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 73-84.	4.7	152
5	Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 906-915.	2.4	152
6	Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 126-135.	4.7	143
7	Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 25-33.	4.7	130
8	Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 32-38.	2.4	126
9	Development of capillary electrophoresis methods for the analysis of fluoroquinolones and application to the study of the influence of humic substances on their photodegradation in aqueous phase. <i>Journal of Chromatography A</i> , 1999, 837, 253-265.	3.7	120
10	Voriconazole Concentration in Human Aqueous Humor and Plasma during Topical or Combined Topical and Systemic Administration for Fungal Keratitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 239-244.	3.2	115
11	Expanding the chemical scope of RNA:methyltransferases to site-specific alkylation of RNA for click labeling. <i>Nucleic Acids Research</i> , 2011, 39, 1943-1952.	14.5	114
12	Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 666-673.	4.7	112
13	Detection of RNA modifications. <i>RNA Biology</i> , 2010, 7, 237-247.	3.1	111
14	Clinical feasibility of dried blood spots: Analytics, validation, and applications. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 130, 231-243.	2.8	109
15	Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations. <i>PLoS ONE</i> , 2013, 8, e67946.	2.5	108
16	High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. <i>Pharmacogenomics Journal</i> , 2012, 12, 499-506.	2.0	100
17	In Vitro Assessment of Methylene Blue on Chloroquine-Sensitive and -Resistant Plasmodium falciparum Strains Reveals Synergistic Action with Artemisinin. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4592-4597.	3.2	99
18	Primary photoproducts and half-lives. <i>Environmental Science and Pollution Research</i> , 1997, 4, 10-15.	5.3	98

#	ARTICLE	IF	CITATIONS
19	Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. <i>Malaria Journal</i> , 2006, 5, 84.	2.3	98
20	Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 676-684.	4.7	98
21	High absolute bioavailability of methylene blue given as an aqueous oral formulation. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 179-189.	1.9	96
22	Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. <i>PLoS ONE</i> , 2011, 6, e27810.	2.5	93
23	GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of mycludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2019, 70, e81.	3.7	93
24	Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 397-405.	4.7	86
25	Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. <i>BMC Clinical Pharmacology</i> , 2006, 6, 6.	2.5	85
26	A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 564-571.	4.7	78
27	Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 576-581.	2.4	75
28	Pharmacokinetics of Sulfbutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2596-2602.	3.2	75
29	Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 709-715.	1.9	73
30	Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3413-3420.	1.6	73
31	MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. <i>Nature Cancer</i> , 2022, 3, 471-485.	13.2	73
32	Preparation and structure of high-chlorinated bornane derivatives for the quantification of toxaphene residues in environmental samples. <i>Fresenius' Journal of Analytical Chemistry</i> , 1993, 346, 779-785.	1.5	71
33	Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 406-413.	4.7	70
34	Spectroscopic characterization of environmentally relevant C10-chloroterpenes from a photochemically modified toxaphene standard. <i>Fresenius' Journal of Analytical Chemistry</i> , 1995, 351, 271-285.	1.5	69
35	Sildenafil Preserves Lung Endothelial Function and Prevents Pulmonary Vascular Remodeling in a Rat Model of Diastolic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 198-206.	3.9	69
36	Trimethoprimâ€™metformin interaction and its genetic modulation by <sc>OCT</sc>2 and <sc>MATE1</sc> transporters. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 787-796.	2.4	67

#	ARTICLE	IF	CITATIONS
37	Photolytic degradation of fluoroquinolone carboxylic acids in aqueous solution. <i>Environmental Science and Pollution Research</i> , 1997, 4, 61-67.	5.3	66
38	Aberrant Expression of Retinoic Acid Signaling Molecules Influences Patient Survival in Astrocytic Gliomas. <i>American Journal of Pathology</i> , 2011, 178, 1953-1964.	3.8	63
39	Identification, Biosynthesis, and Decapping of NAD-Capped RNAs in <i>B.Âsubtilis</i> . <i>Cell Reports</i> , 2018, 24, 1890-1901.e8.	6.4	61
40	Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 86-93.	2.0	60
41	Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. <i>Malaria Journal</i> , 2005, 4, 45.	2.3	59
42	Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1â€²-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 2439-2450.	3.7	59
43	Midazolam microdose to determine systemic and preâ€systemic metabolic <sc>CYP3A</sc> activity in humans. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 278-285.	2.4	59
44	CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 708-712.	4.7	56
45	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	7.2	56
46	Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 2704-2716.	1.5	55
47	Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2350-2361.	3.0	54
48	<sc>CYP3A</sc> activity in severe liver cirrhosis correlates with <sc>C</sc>hildâ€“<sc>P</sc>ugh and model for endâ€stage liver disease (<sc>MELD</sc>) scores. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 160-169.	2.4	53
49	Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 443-444.	2.4	51
50	Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 191-196.	4.7	51
51	Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1535-1545.	3.5	51
52	A multifunctional bioconjugate module for versatile photoaffinity labeling and click chemistry of RNA. <i>Nucleic Acids Research</i> , 2011, 39, 7348-7360.	14.5	50
53	Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. <i>Biochemical Pharmacology</i> , 2013, 85, 265-273.	4.4	50
54	Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. <i>Tropical Medicine and International Health</i> , 2005, 10, 32-38.	2.3	49

#	ARTICLE	IF	CITATIONS
55	Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 863, 273-282.	2.3	49
56	Steady-state pharmacokinetics and metabolism of voriconazole in patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2592-2599.	3.0	49
57	Induction of Voriconazole Metabolism by Rifampin in a Patient with Acute Myeloid Leukemia: Importance of Interdisciplinary Communication To Prevent Treatment Errors with Complex Medications. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3455-3456.	3.2	47
58	Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. <i>PLoS ONE</i> , 2012, 7, e40180.	2.5	47
59	Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 262-265.	2.5	46
60	Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 405-414.	4.7	45
61	Polar photodegradation products of quinolones determined by HPLC/MS/MS. <i>Chemosphere</i> , 1999, 38, 1279-1286.	8.2	44
62	Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 850, 249-258.	2.3	41
63	Bile salt-phospholipid conjugate ursodeoxycholy l lysophosphatidylethanolamide as a hepatoprotective agent. <i>Hepatology</i> , 2009, 50, 143-154.	7.3	41
64	Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3227-3228.	3.2	40
65	Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. <i>Tropical Medicine and International Health</i> , 2010, 15, 713-717.	2.3	40
66	Theoretical consideration of the structural variety in the toxaphene mixture taking into account recent experimental results. <i>Chemosphere</i> , 1994, 28, 245-252.	8.2	38
67	Concentration effect relationship of CYP3A inhibition by ritonavir in humans. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1795-1800.	1.9	38
68	Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. <i>Pharmacogenomics Journal</i> , 2013, 13, 484-489.	2.0	38
69	Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. <i>Biochemical Pharmacology</i> , 2004, 67, 285-292.	4.4	37
70	Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 238-244.	2.8	37
71	Undeclared exposure to St. John's Wort in hospitalized patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 437-441.	2.4	36
72	Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay. <i>Analytical Chemistry</i> , 2018, 90, 9395-9402.	6.5	33

#	ARTICLE	IF	CITATIONS
73	Turquoise to dark green organs at autopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 341-344.	2.8	31
74	Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. European Journal of Clinical Pharmacology, 2013, 69, 507-513.	1.9	31
75	No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz Treatment. Antimicrobial Agents and Chemotherapy, 2010, 54, 4185-4191.	3.2	30
76	Pharmacokinetics, Tissue Concentrations, and Safety of the Antifungal Agent Voriconazole in Chickens. , 2008, 22, 199-207.		29
77	HRGC-ECD and HRGC-NICI SIM quantification of toxaphene residues in selected marine organism by environmentally relevant chlorobornanes as standard. Chemosphere, 1994, 28, 237-243.	8.2	28
78	Vorinostat in refractory soft tissue sarcomas â€“ Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). European Journal of Cancer, 2016, 64, 74-82.	2.8	28
79	Analysis of methylene blue in human urine by capillary electrophoresis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 826, 244-251.	2.3	27
80	Drug Interaction of Efavirenz and Midazolam: Efavirenz Activates the CYP3A-Mediated Midazolam 1â€²-Hydroxylation In Vitro. Drug Metabolism and Disposition, 2012, 40, 1178-1182.	3.3	27
81	High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. Gastroenterology, 2018, 154, 1543-1545.	1.3	27
82	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical Epigenetics, 2019, 11, 188.	4.1	27
83	Isolation and characterization of environmental relevant single toxaphene components. Chemosphere, 1993, 27, 1857-1863.	8.2	26
84	Structure elucidation of the three most important toxaphene congeners by X-ray analysis. Chemosphere, 1994, 28, 2067-2074.	8.2	25
85	Oral Contraception Does Not Alter Single Dose Saquinavir Pharmacokinetics in Women. British Journal of Clinical Pharmacology, 2004, 57, 244-252.	2.4	25
86	Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to Tj ETQq 0,0 rgBT /Overlock 10	1.9	25
87	Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. European Journal of Clinical Pharmacology, 2013, 69, 1785-1793.	1.9	25
88	Sulphobutylether-âˆ²-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. International Journal of Antimicrobial Agents, 2010, 36, 93-94.	2.5	24
89	The NK<sub>1</sub> receptor antagonist aprepitant does not alter the pharmacokinetics of highâ€dose melphalan chemotherapy in patients with multiple myeloma. British Journal of Clinical Pharmacology, 2010, 70, 903-907.	2.4	22
90	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemotherapy and Pharmacology, 2015, 75, 281-291.	2.3	22

#	ARTICLE	IF	CITATIONS
91	Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1528-1537.	2.4	21
92	Cation exchange resins as pharmaceutical carriers for methylene blue: Binding and release. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 582-587.	4.3	20
93	Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3311-3319.	3.0	20
94	Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. <i>Analytical Chemistry</i> , 2015, 87, 12112-12120.	6.5	20
95	A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1013-1026.	2.3	20
96	Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 784, 233-242.	2.3	19
97	The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known CYP2C19 Genotype. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 423-428.	2.5	19
98	Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. <i>Pharmacogenomics</i> , 2015, 16, 1047-1064.	1.3	19
99	Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. <i>Respiration</i> , 2017, 94, 26-37.	2.6	19
100	Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1954-1965.	2.4	19
101	Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1290-1298.	4.7	19
102	Marked differences in the prevalence of chloroquine resistance between urban and rural communities in Burkina Faso. <i>Acta Tropica</i> , 2008, 105, 81-86.	2.0	18
103	Efavirenz Treatment and False-Positive Results in Benzodiazepine Screening Tests. <i>Clinical Infectious Diseases</i> , 2009, 48, 1787-1789.	5.8	18
104	Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency. <i>Medicine (United States)</i> , 2016, 95, e4631.	1.0	18
105	The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 108, 13-22.	4.0	18
106	Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 141-148.	2.4	17
107	Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2903-2913.	2.4	17
108	Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2310-2320.	2.4	17

#	ARTICLE	IF	CITATIONS
109	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1.	3.2	17
110	Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. <i>Aids</i> , 2002, 16, 674-676.	2.2	16
111	Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 813, 27-33.	2.3	15
112	Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1027, 207-213.	2.3	15
113	Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. <i>BMC Pharmacology &amp; Toxicology</i> , 2019, 20, 53.	2.4	15
114	Rapid Target Analysis for Pesticides in Water by Online Coated Capillary Microextraction Combined with Liquid Chromatography and Tandem Mass Spectrometry. <i>Journal of AOAC INTERNATIONAL</i> , 2000, 83, 762-770.	1.5	14
115	Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 964, 212-221.	2.3	14
116	Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 291-298.	2.8	14
117	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IMS/MS Assay. <i>Cancers</i> , 2020, 12, 1897.	3.7	14
118	Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1632-1641.	2.4	14
119	Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. <i>Cancers</i> , 2020, 12, 793.	3.7	14
120	Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2007, 49, 203-207.	1.5	13
121	Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. <i>Glia</i> , 2015, 63, 1850-1859.	4.9	13
122	Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 742-751.	2.8	13
123	Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 328-336.	0.6	13
124	The role of biotic and abiotic degradation processes during the formation of typical toxaphene peak patterns in aquatic biota. <i>Chemosphere</i> , 1999, 39, 563-568.	8.2	12
125	Fluvoxamine Affects Sildenafil Kinetics and Dynamics. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 589-592.	1.4	12
126	Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. <i>Bioanalysis</i> , 2019, 11, 1459-1467.	1.5	12



#	ARTICLE	IF	CITATIONS
127	Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1155-1163.	3.5	12
128	Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations. <i>Frontiers in Pharmacology</i> , 2020, 11, 26.	3.5	12
129	Cellular Pharmacokinetic/Pharmacodynamic Relationship of Platinum Cytostatics in Head and Neck Squamous Cell Carcinoma Evaluated by Liquid Chromatography Coupled to Tandem Mass Spectrometry. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 51-58.	2.5	11
130	Quantification of retinoid concentrations in human serum and brain tumor tissues. <i>Analytica Chimica Acta</i> , 2012, 725, 57-66.	5.4	11
131	Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1538-1549.	2.0	11
132	Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 899-905.	2.0	11
133	Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure. <i>Clinical Infectious Diseases</i> , 2017, 65, 1033-1036.	5.8	11
134	Rapid drug detection in whole blood droplets using a desorption electrospray ionization static profiling approach – a proof-of-concept. <i>Rapid Communications in Mass Spectrometry</i> , 2020, 34, e8614.	1.5	11
135	Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives. <i>Molecules</i> , 2021, 26, 1281.	3.8	11
136	Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports. <i>Journal of Medical Case Reports</i> , 2014, 8, 171.	0.8	10
137	Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	10
138	Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. <i>Biochemical Pharmacology</i> , 2017, 145, 54-63.	4.4	10
139	Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4267.	4.1	10
140	Development and Validation of an LC-MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. <i>ACS Omega</i> , 2020, 5, 24329-24339.	3.5	10
141	Comparative Bioavailability of the Microemulsion Formulation of Cyclosporine (Neoral) With a Generic Dispersion Formulation (Cicloral) in Young Healthy Male Volunteers. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 312-320.	2.0	9
142	Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1199-1204.	2.0	9
143	Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1345, 128-138.	3.7	9
144	Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 151-158.	2.8	9

#	ARTICLE	IF	CITATIONS
145	An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. <i>Bioanalysis</i> , 2019, 11, 887-898.	1.5	9
146	Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. <i>British Journal of Pharmacology</i> , 2021, 178, 3294-3308.	5.4	9
147	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. <i>Clinical and Translational Science</i> , 2021, 14, 487-491.	3.1	9
148	Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 858-874.	2.4	9
149	Reduction of Saquinavir Exposure by Coadministration of Loperamide. <i>Clinical Pharmacokinetics</i> , 2004, 43, 1015-1024.	3.5	8
150	Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. <i>Scientific Reports</i> , 2018, 8, 16316.	3.3	8
151	An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 633-638.	2.8	8
152	Desorption/Ionization-MS Methods for Drug Quantification in Biological Matrices and Their Validation Following Regulatory Guidance. <i>Analytical Chemistry</i> , 2021, 93, 7152-7163.	6.5	8
153	Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. <i>Clinical Pharmacokinetics</i> , 2022, 61, 97-109.	3.5	8
154	Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity. <i>Journal of Stroke</i> , 2022, 24, 88-97.	3.2	8
155	Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 433-439.	2.3	7
156	Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease. <i>Gut</i> , 2022, 71, 842-844.	12.1	7
157	Daily Honey Consumption Does Not Change CYP3A Activity in Humans. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1223-1232.	2.0	6
158	Liposomal Sphingomyelin Influences the Cellular Lipid Profile of Human Lymphoblastic Leukemia Cells without Effect on P-Glycoprotein Activity. <i>Molecular Pharmaceutics</i> , 2013, 10, 1020-1034.	4.6	6
159	Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1433-1440.	2.4	6
160	CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 250-251.	4.7	6
161	Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 142, 84-90.	2.8	6
162	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. <i>Oncology Letters</i> , 2017, 14, 3185-3192.	1.8	6

#	ARTICLE	IF	CITATIONS
163	New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2090-2094.	3.3	6
164	Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 472-479.	2.0	6
165	Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. <i>Pharmaceuticals</i> , 2022, 15, 694.	3.8	6
166	Disease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria. <i>Malaria Journal</i> , 2014, 13, 219.	2.3	5
167	Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2241-2247.	3.0	5
168	Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 1091-1101.	3.0	5
169	Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 71-79.	2.3	5
170	Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 643-654.	3.5	5
171	Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. <i>Journal of Pharmaceutical Analysis</i> , 2020, 10, 233-239.	5.3	5
172	Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma. <i>Analytica Chimica Acta</i> , 2020, 1114, 42-49.	5.4	5
173	Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 789-798.	2.0	5
174	Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 169, 106076.	4.0	5
175	Pre-systemic Elimination of Tilidine: Localization and Consequences for the Formation of the Active Metabolite Nortilidine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 129-133.	2.5	4
176	Advances in Clinical Pharmacology: Rapid Detection of Small Molecules in Solid Samples at Atmospheric Pressure Using Desorption Electrospray Ionization. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 53-54.	2.0	4
177	Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 5645-5654.	3.7	4
178	Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 957-964.	0.6	4
179	Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC2A3) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labeled L-Leucine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3637.	4.1	4
180	In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective Trial. <i>Journal of Palliative Medicine</i> , 2018, 21, 686-688.	1.1	3

#	ARTICLE	IF	CITATIONS
181	Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 135, 77-82.	4.0	3
182	Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 584.	1.6	3
183	Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides – Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 194, 113728.	2.8	3
184	Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 899-907.	1.6	3
185	Rapid and Sensitive Quantification of Intracellular Glycyl-Sarcosine for Semi-High-Throughput Screening for Inhibitors of PEPT-1. <i>Pharmaceutics</i> , 2021, 13, 1019.	4.5	3
186	Effect of Pantoprazole on the Absorption of Hydroxychloroquine A Randomized Drug-Drug Interaction Trial in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 285-290.	1.6	3
187	Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. <i>Pharmaceutics</i> , 2021, 13, 1498.	4.5	3
188	Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 975-987.	1.9	3
189	Structure of the Toxaphene Compound 2,5-endo,6- exo,8,9,9,10,10-Octachlorobornene-2: A Temperature-Dependent Formation of Two Rotamers. <i>Environmental Science &amp; Technology</i> , 2005, 39, 1736-1740.	10.0	2
190	Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activity. <i>Analytical Biochemistry</i> , 2015, 471, 23-25.	2.4	2
191	An Underestimated Factor: The Extent of Cross-Reactions Modifying APIs in Surface-Modified Liposomal Preparations Caused by Comprised Activated Lipids. <i>Molecules</i> , 2020, 25, 4436.	3.8	2
192	Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 186, 113276.	2.8	2
193	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1176, 122781.	2.3	2
194	Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices – A Practical Example. <i>Molecules</i> , 2022, 27, 690.	3.8	2
195	Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma. <i>Analytical Methods</i> , 2019, 11, 5976-5983.	2.7	1
196	Reply to Truffot et al. <i>Clinical Infectious Diseases</i> , 2018, 66, 1644-1646.	5.8	0
197	Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 461-466.	3.0	0
198	Microdosing drugs: a versatile technique to detect and assess drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 447-448.	3.3	0

#	ARTICLE	IF	CITATIONS
199	Higher chlorzoxazone clearance in obese children compared with none-obese peers, an open-label explorative pharmacokinetic study of CYP2E1 activity. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-15-20.	0.0	0
200	Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue. Pharmaceutics, 2022, 14, 762.	4.5	0
201	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. Neuro-Oncology, 2022, 24, i93-i93.	1.2	0